Authors
Latest:
No Half Measures: How Medical Affairs Can Maximize and Measure ValueEducation and knowledge transfer must be prioritized for industry to see sizable improvement in medical affairs.
Latest:
Beyond the Data: Is Blockchain the Answer to Improving Global Health?The COVID-19 pandemic has shifted the adoption of digital platforms in pharma and has made the industry reconsider which technologies can improve global health moving forward.
Latest:
Q&A With Kevin O'Neill, president and CEO of GE HealthCare, Pharmaceutical DiagnosticsO'Neill discusses the company's place in the global market and recent advancements to improve the patient experience.
Latest:
The Manufacturing Edge on Path to MarketFDA backs the benefits of adopting continuous manufacturing, a strategy which has accelerated approval and launch timelines, and its Emerging Technology Program could be a helpful tool.
Latest:
Top cybersecurity threats, challenges pharma companies need to addressLearn about the evolving cyber-threat landscape affecting the pharmaceutical industry and the recommended approach to addressing those threats.
Latest:
Transform Real-World Evidence (RWE) Insights with Innovative Data SolutionsWebinar Date/Time: Wed, Oct 16, 2024 2:00 PM EDT
Latest:
The Future of Telehealth: Evolving COVID Perspectives Offer CluesNew data comparing past vs. present experience with telemedicine during the pandemic uncovers insight on how patients, doctors, and payers view the market post-COVID.
Latest:
Amplifying the Patient VoiceJo Fearnhead-Wymbs discusses how and why amplifying the patient voice is driving change in the industry for the better.
Latest:
The Rise of EU Protectionism and M&A in Life SciencesChristine Phillips looks at how an increase in protectionism across the EU member states with respect to foreign direct investment impacts the life sciences sector.
Latest:
The Untapped Potential of Behavioral Science in Medical AffairsHistorically, Medical Affairs teams have relied on reporting only empirical evidence such as efficacy and tolerability profiles to influence uptake of a new drug or therapy. Here, Ben Routley and Mark Pringle explore the scope for applying behavioral science techniques to improve the impact of client communications.
Latest:
AI + Social Media: The Intersection of 2 Contemporary Inventions Takes Physician Engagement to the Next LevelThe two technologies are helping HCPs spread information and collect data in new ways.
Latest:
Mastering Patient Centricity’s Moving Parts: Innovators Share Real-World ExamplesAgility and better decisions depend on managing risk and gaining insights from data by prioritizing patient and end-user needs. Companies of all sizes, including GSK, Boehringer-Ingelheim, Sanofi, AstraZeneca, and AbbVie, share best practices.
Latest:
From Endemic to POC: The Journey Pharma Marketers Need to TreadThe digital revolution has brought more efficient ways to reach and touch HCPs.
Latest:
Merck Medical Affairs: An Enterprise-Wide Approach to Customer IntelligenceThe importance of enabling customer intelligence at scale.
Latest:
Optimized for Growth? Revenue Management in PharmaAccording to the latest State of Revenue survey of c-suite executives, pharma manufacturers are prioritizing digital transformation while struggling with inflation and supply chain disruptions.
Latest:
Refining, Rethinking, and Decentralizing Clinical ResearchDecentralized tools and technologies will continue to provide new opportunities for patient engagement post-COVID.
Latest:
Healthy Planet, Healthy People: How Pharma Can Lead the WayReaching new heights in sustainability a win-win for industry.
Latest:
Janssen, Johns Hopkins Partner on Dermatology Ethnic Skin ProgramJanssen, Johns Hopkins Dermatology’s Ethnic Skin Fellowship Program partnership focuses on improving clinical care and advancing research for skin-of-color patients.
Latest:
Harnessing China’s Global OpportunitySy Chyi Yeoh looks at some of the practical considerations faced by Chinese firms looking to expand overseas.
Latest:
Uncovering the Potential of Advanced Analytics in International Price ManagementHow can pharmaceutical companies successfully apply advanced analytics? Pricing experts from Simon-Kucher & Partners identify the hurdles and winning approaches.
Latest:
China’s 2022 NRDL ReadoutDespite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.
Latest:
Digital-Deal Alignment: Considerations for Tech AgreementsThe eight key areas biopharma manufacturers must stay on top of when planning and executing alliance agreements with prospective digital health partners.
Latest:
‘Risk-Sharing’ as a Tool for Enabling Fast Access to COVID-19 VaccinesIn a time of global pandemic, traditional vaccine procurement schemes are not fit for purpose and need to adapt to allow both governments and manufacturers the ability to manage a greater level of risk associated with rapid vaccine development and deployment.
Latest:
Use Behavioral Science for Better Launch SuccessUnderstanding of human behavior can aid in avoiding pitfalls during launch.
